SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SteveG who wrote (69)8/24/1997 9:02:00 PM
From: SteveG   of 496
 
<They also have Dopascan (phase IIb data will be presented next month), second generation Gliadel studies, plus phase III Gliadel to expand to primary surgeries, and RPR may expand deal to include Taxol/Taxotere wafers.>

In addition, they also have their presynaptic glutamate uptake inhibitor, whose Na+ channel antagonist's neuroprotective effects in reducing infarc volume in temporary focal ischemia may well find a significant market in stroke and head trauma use.

Steve
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News